Australia's most trusted
source of pharma news
Thursday, 06 February 2025
Posted 3 February 2025 AM
Competition in the haemophilia market is heating up after the TGA approved Pfizer's Hympavzi, marking only the second anti-TFPI antibody available in Australia following Novo Nordisk's Alhemo.
Unlike Alhemo which is given once-daily under the skin, Hympavazi, also known as marstacimab, is administered subcutaneously once-weekly.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.